Key Developments: Verisante Technology Inc (VRSEF.PK)
0.36USD
18 Jun 2013
$0.01 (+3.99%)
$0.34
$0.35
$0.36
$0.35
8,850
37,658
$0.66
$0.28
Latest Key Developments (Source: Significant Developments)
Verisante Technology Inc Announces Exclusive Distribution Agreement With Frontiere Medicale Europe LLC For The UK And Ireland
Verisante Technology Inc announced that it has entered into an exclusive agreement with Frontiere Medicale EUROPE LLC. to distribute Verisante Aura in the UK and Ireland. Full Article
Verisante Technology Inc Completes Private Placement
Verisante Technology Inc announced that it has closed its brokered private placement of 2,357,500 units (Units) at a price of $0.40 per Unit for gross proceeds of $943,000 led by sole agent Raymond James Ltd. (the Agent). Each Unit consists of one common share of the Company and one common share purchase warrant (a Warrant). Each Warrant entitles the holder to acquire a common share at a price of $0.60 for a period of 24 months from the date of issuance. Full Article
Verisante Technology Inc Announces Brokered Private Placements
Verisante Technology Inc announced that the Company intends to complete two separate and independent brokered private placements through Raymond James Ltd. (agent for sales in Canada only) and a separate Agent for sales in the US (the Agents). The private placement to be conducted by Raymond James Ltd. shall be for a minimum of 4,000,000 to a maximum of 10,000,000 units at $0.50 per unit for total gross proceeds of a minimum of $2,000,000 and a maximum of $5,000,000, and the private placement to be conducted by the Company's US Agent shall be for a minimum of 4,000,000 to a maximum of 10,000,000 units at $0.50 per unit for total gross proceeds of a minimum of $2,000,000 and a maximum of $5,000,000, (collectively, the Offerings). Each unit will comprise of one common share and one common share purchase warrant (the Warrants). Each Warrant will entitle the holder to purchase one common share at a price of $0.70 per share with an expiry date of 24 months from the closing of the Offerings. Closing of the Offerings are scheduled to occur on or before April 30, 2013 or at any other such time as the Company and each Agent may agree. The net proceeds of the Offerings will be used to fund the Company's manufacturing of Aura, to pursue additional regulatory approvals of Aura in the United States and other regions, to support sales and marketing initiatives, and for working capital requirements. Full Article
Verisante Technology Inc Announces Exclusive Distribution Agreement with Pacifica Handels AG for Switzerland
Verisante Technology Inc announced that the Company has entered into an exclusive agreement with Pacifica Handels AG to distribute Verisante Aura in Switzerland. Pacifica is based in Baar, Switzerland and distributes products for the global manufacturer of medical laser and IPL systems for use in aesthetics, dermatology, and other applications. Aura is a complementary addition to the Company's existing product line. Full Article
Verisante Technology Inc Extends Research Agreement With BC Cancer Agency
Verisante Technology Inc announced that the Company has renewed its Collaborative Research Agreement (CRA) with the BC Cancer Agency (the Agency) for another 13 months. Verisante will contribute approximately $250,000 over the course of the CRA to fund continued development of the Company's Aura(TM) device for skin cancer detection and fund further research and development of the Company's Core(TM) device for the detection of lung, gastro-intestinal and cervical cancers. Full Article
Verisante Technology Inc Announces Health Canada Approval for Verisante Aura
Verisante Technology Inc announced that it has obtained a licence from Health Canada to market and sell the Verisante Aura, non-invasive medical device for the early detection of skin cancer. Full Article
Earnings vs. 
Estimates
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
